vs
FIRST FINANCIAL BANKSHARES INC（FFIN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
FIRST FINANCIAL BANKSHARES INC的季度营收约是再鼎医药的1.3倍（$164.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs 12.0%），FIRST FINANCIAL BANKSHARES INC自由现金流更多（$286.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.7%）
第一金融银行股份有限公司（FFIN）是总部位于印第安纳州特雷霍特的区域银行，由第一金融集团运营。它是印第安纳州历史最悠久的全国性银行，在美国全国性银行中历史排名第五，其母公司第一金融集团也是维戈县唯一的上市企业。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FFIN vs ZLAB — 直观对比
营收规模更大
FFIN
是对方的1.3倍
$127.1M
营收增速更快
ZLAB
高出5.1%
12.0%
自由现金流更多
FFIN
多$312.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.7M | $127.1M |
| 净利润 | $73.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 54.4% | -54.6% |
| 净利率 | 44.5% | — |
| 营收同比 | 12.0% | 17.1% |
| 净利润同比 | 17.6% | — |
| 每股收益（稀释后） | $0.51 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFINZLAB
| Q4 25 | $164.7M | $127.1M | ||
| Q3 25 | $161.3M | $115.4M | ||
| Q2 25 | $156.6M | $109.1M | ||
| Q1 25 | $149.0M | $105.7M | ||
| Q4 24 | $147.1M | $108.5M | ||
| Q3 24 | $139.5M | $101.8M | ||
| Q2 24 | $134.5M | $100.1M | ||
| Q1 24 | $129.6M | $87.1M |
净利润FFINZLAB
| Q4 25 | $73.3M | — | ||
| Q3 25 | $52.3M | $-36.0M | ||
| Q2 25 | $66.7M | $-40.7M | ||
| Q1 25 | $61.3M | $-48.4M | ||
| Q4 24 | $62.3M | — | ||
| Q3 24 | $55.3M | $-41.7M | ||
| Q2 24 | $52.5M | $-80.3M | ||
| Q1 24 | $53.4M | $-53.5M |
毛利率FFINZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率FFINZLAB
| Q4 25 | 54.4% | -54.6% | ||
| Q3 25 | 39.2% | -42.3% | ||
| Q2 25 | 52.2% | -50.3% | ||
| Q1 25 | 50.4% | -53.3% | ||
| Q4 24 | 51.7% | -62.6% | ||
| Q3 24 | 48.3% | -66.6% | ||
| Q2 24 | 47.3% | -76.0% | ||
| Q1 24 | 50.0% | -80.7% |
净利率FFINZLAB
| Q4 25 | 44.5% | — | ||
| Q3 25 | 32.4% | -31.2% | ||
| Q2 25 | 42.6% | -37.3% | ||
| Q1 25 | 41.2% | -45.8% | ||
| Q4 24 | 42.4% | — | ||
| Q3 24 | 39.7% | -40.9% | ||
| Q2 24 | 39.0% | -80.2% | ||
| Q1 24 | 41.2% | -61.4% |
每股收益（稀释后）FFINZLAB
| Q4 25 | $0.51 | $-0.05 | ||
| Q3 25 | $0.36 | $-0.03 | ||
| Q2 25 | $0.47 | $-0.04 | ||
| Q1 25 | $0.43 | $-0.04 | ||
| Q4 24 | $0.43 | $-0.09 | ||
| Q3 24 | $0.39 | $-0.04 | ||
| Q2 24 | $0.37 | $-0.08 | ||
| Q1 24 | $0.37 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $715.5M |
| 总资产 | $15.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FFINZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益FFINZLAB
| Q4 25 | $1.9B | $715.5M | ||
| Q3 25 | $1.8B | $759.9M | ||
| Q2 25 | $1.7B | $791.7M | ||
| Q1 25 | $1.7B | $810.8M | ||
| Q4 24 | $1.6B | $840.9M | ||
| Q3 24 | $1.7B | $667.7M | ||
| Q2 24 | $1.5B | $704.2M | ||
| Q1 24 | $1.5B | $762.2M |
总资产FFINZLAB
| Q4 25 | $15.4B | $1.2B | ||
| Q3 25 | $14.8B | $1.2B | ||
| Q2 25 | $14.4B | $1.2B | ||
| Q1 25 | $14.3B | $1.2B | ||
| Q4 24 | $14.0B | $1.2B | ||
| Q3 24 | $13.6B | $985.3M | ||
| Q2 24 | $13.2B | $987.4M | ||
| Q1 24 | $13.2B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $299.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $286.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 173.6% | -21.0% |
| 资本支出强度资本支出/营收 | 8.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.08× | — |
| 过去12个月自由现金流最近4个季度 | $503.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FFINZLAB
| Q4 25 | $299.4M | $-26.0M | ||
| Q3 25 | $86.5M | $-32.0M | ||
| Q2 25 | $61.3M | $-31.0M | ||
| Q1 25 | $76.8M | $-61.7M | ||
| Q4 24 | $309.6M | $-55.8M | ||
| Q3 24 | $80.7M | $-26.8M | ||
| Q2 24 | $68.8M | $-42.2M | ||
| Q1 24 | $75.6M | $-90.1M |
自由现金流FFINZLAB
| Q4 25 | $286.0M | $-26.7M | ||
| Q3 25 | $83.7M | $-35.0M | ||
| Q2 25 | $58.7M | $-33.9M | ||
| Q1 25 | $74.7M | $-63.2M | ||
| Q4 24 | $292.9M | $-58.4M | ||
| Q3 24 | $77.7M | $-28.2M | ||
| Q2 24 | $63.8M | $-42.9M | ||
| Q1 24 | $71.7M | $-91.1M |
自由现金流率FFINZLAB
| Q4 25 | 173.6% | -21.0% | ||
| Q3 25 | 51.9% | -30.4% | ||
| Q2 25 | 37.5% | -31.1% | ||
| Q1 25 | 50.1% | -59.9% | ||
| Q4 24 | 199.1% | -53.8% | ||
| Q3 24 | 55.7% | -27.7% | ||
| Q2 24 | 47.4% | -42.9% | ||
| Q1 24 | 55.3% | -104.5% |
资本支出强度FFINZLAB
| Q4 25 | 8.2% | 0.5% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 1.4% | 1.5% | ||
| Q4 24 | 11.4% | 2.4% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 3.7% | 0.7% | ||
| Q1 24 | 3.0% | 1.1% |
现金转化率FFINZLAB
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 1.25× | — | ||
| Q4 24 | 4.97× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIN
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
